Vericiguat in Heart Failure with Reduced Ejection Fraction: Evidence from Pooled Analyses of VICTORIA and VICTOR Trials
Highlight
– Vericiguat reduces the composite risk of cardiovascular death or heart failure hospitalization in patients with HFrEF across a broad risk spectrum.
– The pooled analysis from the VICTORIA and VICTOR trials includes diverse populations with and without recent worsening of heart failure.
– Both components of the composite endpoint—cardiovascular death and heart failure hospitalization—showed statistically significant reductions.
– These findings support vericiguat as an additional treatment option in contemporary guideline-directed medical therapy for HFrEF.
Study Background
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.